Pharmacokinetics, Pharmacodynamics and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients

Population pharmacokinetic (popPK) modeling was used to characterize the PK profile of the oral janus kinase (JAK)1/JAK2 inhibitor, baricitinib, in 18 patients with Mendelian interferonopathies who are enrolled in a compassionate use program. Patients received doses between 0.1 to 17 mg per day. Cov...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:Clin Pharmacol Ther
Κύριοι συγγραφείς: Kim, Hanna, Brooks, Kristina M., Tang, Cheng Cai, Wakim, Paul, Blake, Mary, Brooks, Stephen R., Sanchez, Gina A. Montealegre, de Jesus, Adriana A., Huang, Yan, Tsai, Wanxia Li, Gadina, Massimo, Prakash, Apurva, Janes, Jonathan Marcus, Zhang, Xin, Macias, William L., Kumar, Parag, Goldbach-Mansky, Raphaela
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: 2017
Θέματα:
Article
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6089664/
https://ncbi.nlm.nih.gov/pubmed/29134648
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.936
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια